Redcare Pharmacy's Analyst Optimism Collides With a Market Focused on the July Slowdown
Published on 08/05/2026 at 16:34 | Redaktion boerse-global.de
The gap between what the sell-side models project and what the tape actually shows has rarely been wider for Redcare Pharmacy. Ten analysts cover the online pharmacy, nine carry buy ratings, and the average price target sits at €97 — roughly 56 percent above the current share price. Yet the stock keeps sliding, down another 2.05 percent on Wednesday and nearly 10 percent over the past seven trading sessions.
That disconnect has a name: the July growth slowdown. After two quarters of explosive prescription-volume gains, analysts now expect the monthly growth rate to dip below 20 percent — a noticeable deceleration from the pace that drove the Rx segment up 58 percent in the second quarter. Add in seasonally softer third-quarter demand, and investors have found plenty of reasons to stay on the sidelines despite a legislative win that should have been unequivocally positive for the company.
Berlin Lends a Hand, the Market Looks the Other Way
Germany's parliament has passed the long-debated pharmacy reform, and for Redcare the details matter. The fixed dispensing fee rises to €9.00 and is scheduled to climb to €9.50 by early 2027. More importantly, the law draws a clean line between pharmaceutical duties and external logistics — a separation that analysts read as meaningful legal protection for the delivery models of large online pharmacies. Legal challenges to their supply chains should lose traction.
The reform also sets the stage for a technical transition. CardLink, the NFC-based system that lets patients redeem prescriptions via smartphone, will be replaced in 2026 by PoPP — "Proof of Patient Presence" — which introduces stricter security requirements including biometric verification such as Face ID or fingerprint recognition. Management has signaled confidence in a smooth migration, viewing mobile prescription redemption as a pillar of German Rx growth.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
Record Margins, Falling Share Price
The second-quarter numbers themselves told a story of operational progress. Revenue reached €853 million, and the adjusted EBITDA margin hit 3.5 percent — a ten-year high. The company's active customer base has grown to 14.7 million, up from 13.1 million at the start of the year, evidence for bulls that the model scales.
None of that has stopped the bleeding in the stock. At Tuesday's close of €63.55, the shares had lost 0.94 percent on the day, with the 50-day moving average at €61.45 offering the nearest technical support. The stock sits roughly 39 percent below its year-high of €103.60, and the 52-week peak of €104.80 — reached almost exactly a year ago — is now more than 40 percent in the rearview mirror. Year to date, the shares are down 5.4 percent; over twelve months, the decline approaches 40 percent.
Banks Hold Their Ground
The analyst community has responded to the July slowdown with a collective shrug. On August 4, several major banks updated their assessments — all in the same direction. Warburg Research leads the pack with a €116 price target, followed by Deutsche Bank at €103 and Berenberg at €94. Baader Bank and UBS sit at the lower end with €85 and €74 respectively, though both confirm upside. Jefferies maintains its buy rating with an €83 target.
Redcare Pharmacy at a turning point? This analysis reveals what investors need to know now.
The optimism rests on the earnings trajectory rather than the current tape. For fiscal 2026, consensus sees revenue of €3.41 billion, with net losses expected to shrink by roughly 70 percent year over year. Management, meanwhile, holds to its full-year guidance of 15 to 17 percent revenue growth. CEO Olaf Heinrich and CFO Jasper Eenhorst have stressed that the company remains on track.
The market's skepticism may ultimately be resolved by the third-quarter report. Whether the projected loss reduction for 2026 is enough to close the gap between analyst targets and the share price is a question that only the next set of numbers can answer — and until then, the divergence between Wall Street's spreadsheets and the trading floor's mood looks set to persist.
Ad
Redcare Pharmacy Stock: New Analysis - 5 August
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
